Evidence-based clinical practice guidelines for prostate cancer (summary - JUA 2006 edition)

International Journal of Urology

Volumn 15, Issue 1, 2008, Pages 1-18

  Kamidono, Sadao ^a   Ohshima, Shinichi ^a   Hirao, Yoshihiko ^a,b   Suzuki, Kazuhiro ^a   Arai, Yoichi ^a   Fujimoto, Hiroyuki ^a   Egawa, Shin ^a   Akaza, Hideyuki ^a   Hara, Isao ^a   Hinotsu, Shiro ^a   Kakehi, Yoshiyuki ^a   Hasegawa, Tomonori ^a  

^a Working Group for Creation of Clinical Practice Guidelines for Prostate Cancer

^b NARA MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER RISK; CANCER SCREENING; CANCER STAGING; CANCER SURGERY; CLINICAL PRACTICE; EVIDENCE BASED MEDICINE; EVIDENCE BASED PRACTICE; HUMAN; MORBIDITY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; WATCHFUL WAITING;

AGED; AGED, 80 AND OVER; ANDROGEN ANTAGONISTS; DIGITAL RECTAL EXAMINATION; EVIDENCE-BASED MEDICINE; GONADOTROPIN-RELEASING HORMONE; HUMANS; JAPAN; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PALLIATIVE CARE; PATIENT SELECTION; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; RADIOTHERAPY; RISK FACTORS; UROLOGY;

EID: 37849009064     PISSN: 09198172     EISSN: 14422042     Source Type: Journal    
DOI: 10.1111/j.1442-2042.2007.01959.x     Document Type: Review

References (185)

1. Ohno Y, Nakamura T, Oshima A et al. The future estimates of cancer prevalence rate in Japan. In : Oshima A, Kuroishi T, Tajima K (eds). Gan Tohkei Hakusho-Morbidity/Death/Prognosis-2004. Shinohara Publisher, Tokyo, 2004 201 217.
2. Cancer Statistics in Japan ′03: Age-adjusted Death Rates of Malignant Neoplasms by Site, Sex and Calendar Year (1950-2001). [Cited 27 July 2004.] Available from URL: http://www.ncc.go.jp/jp/statistics/2003/data05.pdf
3. Yatani R, Chigusa I, Akazaki K et al. Geographic pathology of latent prostatic carcinoma. Int. J. Cancer 1982 29 : 611 16.
4. Etzioni R, Cha R, Feuer EJ et al. Asymptomatic incidence and duration of prostate cancer. Am. J Epidemiol. 1998 148 : 775 85.
5. Hiraishi T et al. Latent Prostatic Carcinoma. Clinical Practice Manual for Prostate Cancer, The Japanese Foundation for Prostate Research, Kanehara & Co., LTD., Tokyo, 1995 13 24.
6. Watanabe H. Studies on the Natural History of Prostate Cancer. Clinical Practice Manual for Prostate Cancer, The Japanese Foundation for Prostate Research, Kanehara & Co., LTD., Tokyo, 1995 1 12.
7. Fukuta F, Masumori N, Tanaka Y et al. The detection rate of prostate cancer in outpatients presenting lower urinary tract symptoms. Jpn. J. Clin. Urol. 2005 59 : 133 8.
8. Lepor H, Owens RS, Rogenes V et al. Detection of prostate cancer in males with prostatism. Prostate 1994 25 : 132 40.
9. Steinberg GD, Carter BS, Beaty TH et al. Family history and the risk of prostate cancer. Prostate 1990 17 : 337 47.
10. Giovannucci E, Rimm EB, Colditz GA et al. A prospective study of dietary fat and risk of prostate cancer. J. Natl. Cancer Inst. 1993 85 : 1571 9.
11. Nakata S, Imai K, Yamanaka H, Yashima H. Correlation Analysis between Mortality for Prostate Cancer and Dietary Pattern in Japan and the World. Jpn. J. Cancer Clin. 1994 40 : 831 6.
12. Hebert JR, Hurley TG, Olendzki BC et al. Nutritional and socioeconomic factors in relation to prostate cancer mortality: a cross-national study. J. Natl. Cancer Inst. 1998 90 : 1637 47.
13. Eichholzer M, Stahelin HB, Ludin E et al. Smoking, plasma vitamins C, E, retinol, and carotene, and fatal prostate cancer: seventeen-year follow-up of the prospective Basel study. Prostate 1999 : 38 : 189 98.
14. Clark LC, Dalkin B, Krongrad A et al. Decreased incidence of prostate cancer with selenium supplementation: results of a double-blind cancer prevention trial. Br. J. Urol. 1998 81 : 730 4.
15. Hartman TJ, Albanes D, Pietinen P et al. The association between baseline vitamin E, selenium, and prostate cancer in the alpha-tocopherol, beta-carotene cancer prevention study. Cancer Epidemiol. Biomarkers Prev. 1998 7 : 335 40.
16. Smith RA, Cokkinides V, Eyre HJ et al. American Cancer Society guidelines for the early detection of cancer, 2004. CA Cancer J. Clin. 2004 54 : 41 52.
17. American Urological Association (AUA). Prostate-specific antigen (PSA) best practice policy. Oncology (Williston Park) 2000 14 : 267 72, 277 28, 280 passim.
18. Recommendations and Rationale. Screening for Prostate Cancer: U.S. Preventive Services Task Force (USPSTF). [Cited 12 November 2004.] Available from URL: http://www.ahcpr.gov/clinic/3rduspstf/prostatescr/prostaterr.htm
19. Harris R, Lohr KN. Screening for prostate cancer: an update of the evidence for the U.S. Preventive Services Task Force. Ann. Intern. Med. 2002 137 : 917 29.
20. Roberts RO, Bergstralh EJ, Katusic SK et al. Decline in prostate cancer mortality from 1980 to 1997, and an update on incidence trends in Olmsted County, Minnesota. J. Urol. 1999 161 : 529 33.
21. Meyer F, Moore L, Bairati I et al. Downward trend in prostate cancer mortality in Quebec and Canada. J. Urol. 1999 161 : 1189 91.
22. Bartsch G, Horninger W, Klocker H et al. Prostate cancer mortality after introduction of prostate-specific antigen mass screening in the Federal State of Tyrol, Austria. Urology 2001 58 : 417 24.
23. Prorok PC, Andriole GL, Bresalier RS et al. Design of the Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening trial. Control. Clin. Trials 2000 21 (6 Suppl 273S 309S.
24. Schröder FH, Denis LJ, Roobol M et al. The story of the European randomized study of screening for prostate cancer. BJU Int. 2003 92 (Suppl 2 1 13.
25. The Prostate Cancer Screening Council, The Japanese Foundation for Prostate Research. The survey of prostate cancer screening tests in Ningen Dock in Japan (1989-1999). The survey of prostate cancer mass screening in Japan (1986-1999). Jpn. J. Urol. Surg. 2003 16 : 1023 38.
26. Kubota Y, Ito K, Imai K et al. Effectiveness of mass screening for the prognosis of prostate cancer patients in Japanese communities. Prostate 2002 50 : 262 9.
27. Ito K, Yamamoto T, Suzuki K et al. The risk of rapid prostate specific antigen increase in men with baseline prostate specific antigen 20 ng/ml or less. J. Urol. 2004 171 : 656 60.
28. Ito K, Yamamoto T, Ohi M et al. Possibility of re-screening intervals of more than one year in men with PSA levels of 40 ng/ml or less. Prostate 2003 57 : 8 13.
29. Cancer Registration Committee of the Japanese Urological Association. Clinicopathological statistics on registered prostate cancer patients in Japan: 2000 report from the Japanese Urological Association. Int. J. Urol. 2005 12 : 46 61.
30. Chodak GW. Early detection and screening for prostatic cancer. Urology 1989 34 : 10.
31. Pedersen KV, Carlsson P, Varenhorst E et al. Screening for carcinoma of the prostate by digital rectal examination in a randomly selected population. BMJ 1990 300 : 1041.
32. Catalona WJ, Richie JP, Ahmann FR et al. Comparison of digital rectal examination and serum prostate specific antigen (PSA) in the early detection of prostate cancer: results of a multicenter clinical trial of 6630 men. J. Urol. 1994 151 : 1283 90.
33. Haas GP, Monyie JE, Pontes JE. The state of prostate cancer screening in the United States. Eur. Urol. 1993 23 : 337 47.
34. Gretzer MB, Partin AW. PSA markers in prostate cancer detection. Urol. Clin. North Am. 2003 30 : 677 86.
35. Okihara K, Cheli CD, Partin AW et al. Comparative analysis of complexed prostate specific antigen, free prostate specific antigen and their ratio in detecting prostate cancer. J. Urol. 2002 167 : 2017 23.
36. Elgamal AA, van Poppel HP, van de Voorde WM et al. Impalpable, invisible stage T1c prostate cancer: characteristics and clinical relevance in 100 radical prostatectomy specimens-a different view. J. Urol. 1997 157 : 244 50.
37. Gustavsson O, Norming U, Almgard LE et al. Diagnostic methods in the detection of prostate cancer: a study of a randomly selected population of 2400 men. J. Urol. 1992 148 : 1827 31.
38. Mettlin C, Murphy GP, Babaian RJ et al. The results of a five-year early prostate cancer detection intervention. Investigators of the American Cancer Society National Prostate Cancer Detection Project. Cancer 1996 77 : 150 9.
39. Punglia RS, D'Amico AV, Catalona WJ et al. Effect of verification bias on screening for prostate cancer by measurement of prostate-specific antigen. N. Engl. J. Med. 2003 349 : 335 42.
40. Hodge KK, McNeal JE, Terris MK et al. Random systemic versus directed ultrasound guided transrectal core biopsies of the prostate. J. Urol. 1989 142 : 71 4.
41. Emiliozzi P, Corsetti A, Tassi B et al. Best approach for prostate cancer detection: a prospective study on transperineal versus transrectal six-core prostate biopsy. Urology 2003 61 : 961 6.
42. Emiliozzi P, Longhi S, Scarpone P et al. The value of a single biopsy with 12 transperineal cores for detecting prostate cancer in patients with elevated prostate specific antigen. J. Urol. 2001 166 : 845 50.
43. Raaijmakers R, Kirkels WJ, Roobol MJ et al. Complication rates and risk factors of 5802 transrectal ultrasound-guided sextant biopsies of the prostate within a population-based screening program. The Neth. Urol. 2002 60 : 826 30.
44. Babaian RJ, Toi A, Kamoi K et al. A comparative analysis of sextant and an extended 11-core multisite directed biopsy strategy. J. Urol. 2000 163 : 152 7.
45. Presti JC Jr, Chang JJ, Bhargava V et al. The optimal systematic prostate biopsy scheme should include 8 rather than 6 biopsies: results of a prospective clinical trial. J. Urol. 2000 163 : 163 6 discussion 166 7.
46. Keetch DW, Catalona WJ, Smith DS. Serial prostate biopsies in men with persistently elevated serum prostate specific antigen levels. J. Urol. 1994 151 : 1571 4.
47. Roerhborn CG, Pickers GJ, Sanders JS. Diagnostic yield of repeated ultrasound guided biopsies stratified by specific histopathologic diagnosis and prostate specific antigen levels. Urology 1996 47 : 347 52.
48. Zlotta AR, Raviv G, Schulman CC. Clinical prognostic criteria for later diagnosis of prostate carcinoma in patients with initial isolated prostatic intraepithelial neoplasia. Eur. Urol. 1996 30 : 249 55.
49. Haggman MJ, Macoska JA, Wojno KJ et al. The relationship between prostatic intraepithelial neoplasia and prostate cancer: critical issues. J. Urol. 1997 158 : 12 22.
50. Spigelman SS, McNeal JE, Freiha FS et al. Rectal examination in volume determination of carcinoma of the prostate: clinical and anatomical correlations. J. Urol. 1986 136 : 1228 30.
51. Partin AW, Mangold LA, Lamm DM et al. Contemporary update of prostate cancer staging nomograms (Partin Tables) for the new millennium. Urology 2001 58 : 843 8.
52. Rorvik J, Halvorsen OJ, Servoll E et al. Transrectal ultrasonography to assess local extent of prostatic cancer before radical prostatectomy. Br. J. Urol. 1994 73 : 65 9.
53. Lee N, Newhouse JH, Olsson CA et al. Which patients with newly diagnosed prostate cancer need a computed tomography scan of the abdomen and pelvis? An analysis based on 588 patients. Urology 1999 54 : 490 4.
54. Jager GJ, Severens JL, Thornbury JR et al. Prostate cancer staging: should MR imaging be used? A decision analytic approach. Radiology 2000 215 : 445 51.
55. Heenan SD. Magnetic resonance imaging in prostate cancer. Prostate Cancer Prostatic Dis. 2004 7 : 282 8.
56. Partin AW, Yoo J, Carter HB et al. The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer. J. Urol. 1993 150 : 110 14.
57. Whitmore WF Jr. Natural history and staging of prostate cancer. Urol. Clin. North Am. 1984 11 : 209 20.
58. Gerber G, Chodak GW. Assessment of value of routine bone scans in patients with newly diagnosed prostate cancer. Urology 1991 37 : 418 22.
59. Soloway MS, Hardeman SW, Hickey D et al. Stratification of patients with metastatic prostate cancer based on extent of disease on initial bone scan. Cancer 1988 61 : 195 202.
60. Rana A, Karamanis K, Lucas MG et al. Identification of metastatic disease by T category, Gleason score and serum PSA level in patients with carcinoma of the prostate. Br. J. Urol. 1992 69 : 277 81.
61. Oesterling JE. Prostate specific antigen: a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. J. Urol. 1991 145 : 907 23.
62. Oesterling JE. Using PSA to eliminate the staging radionuclide bone scan. Significant economic implications. Urol. Clin. North Am. 1993 20 : 705 11.
63. Nakayama T. Guide to Developing and Using Evidence-Based Practice Guidelines. Kanehara & Co., LTD., Tokyo, 2004.
64. D'Amico AV, Moul JW, Carroll PR et al. Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy. J. Natl. Cancer Inst. 2003 95 : 1376 83.
65. Iselin CE, Robertson JE, Paulson DF. Radical perineal prostatectomy: oncological outcome during a 20-year period. J. Urol. 1999 161 : 163 8.
66. D'Amico AV. Predicting prostate-specific antigen recurrence established: now, who will survive? J. Clin. Oncol. 2002 20 : 3188 90.
67. Schild SE, Wong WW, Novicki DE et al. Detection of residual prostate cancer after radical prostatectomy with the Abbott IMx PSA assay. Urology 1996 47 : 878 81.
68. Oefelein MG, Smith N, Carter M et al. The incidence of prostate cancer progression with undetectable serum prostate specific antigen in a series of 394 radical prostatectomies. J. Urol. 1995 154 : 2128 31.
69. Pound CR, Partin AW, Eisenberger MA et al. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 1999 281 : 1591 7.
70. Scher HI. Management of prostate cancer after prostatectomy: treating the patient, not the PSA. JAMA 1999 281 : 1642 5.
71. Lu-Yao GL, Yao SL. Population-based study of long-term survival in patients with clinically localised prostate cancer. Lancet 1997 349 (9056 906 10.
72. Graversen PH, Nielsen KT, Gasser TC et al. Radical prostatectomy versus expectant primary treatment in stages I and II prostatic cancer. A fifteen-year follow-up. Urology 1990 36 : 493 8.
73. Barry MJ, Albertsen PC, Bagshaw MA et al. Outcomes for men with clinically nonmetastatic prostate carcinoma managed with radical prostactectomy, external beam radiotherapy, or expectant management: a retrospective analysis. Cancer 2001 91 : 2302 14.
74. Holmberg L, Bill-Axelson A, Helgesen F et al. Scandinavian Prostatic Cancer Group Study Number 4. A randomized trial comparing radical prostatectomy with watchful waiting in early prostate cancer. N. Engl. J. Med. 2002 347 : 781 9.
75. Elgamal AA, Van Poppel HP, Van de Voorde WM et al. Impalpable invisible stage T1c prostate cancer: characteristics and clinical relevance in 100 radical prostatectomy specimens-a different view. J. Urol. 1997 157 : 244 50.
76. Oesterling JE, Suman VJ, Zincke H et al. PSA-detected (clinical stage T1c or B0) prostate cancer. Pathologically significant tumors. Urol. Clin. North Am. 1993 20 : 687 93.
77. Epstein JI, Walsh PC, Brendler CB. Radical prostatectomy for impalpable prostate cancer: the Johns Hopkins experience with tumors found on transurethral resection (stages T1A and T1B) and on needle biopsy (stage T1C). J. Urol. 1994 152 : 1721 9.
78. Gibbons RP. Total prostatectomy for clinically localized prostate cancer: long-term surgical results and current morbidity. NCI Monogr. 1988 7 : 123 6.
79. Pound CR, Partin AW, Epstein JI et al. Prostate-specific antigen after anatomic radical retropubic prostatectomy. Patterns of recurrence and cancer control. Urol. Clin. North Am. 1997 24 : 395 406.
80. Catalona WJ, Smith DS. 5-year tumor recurrence rates after anatomical radical retropubic prostatectomy for prostate cancer. J. Urol. 1994 152 : 1837 42.
81. Trapasso JG, deKernion JB, Smith RB et al. The incidence and significance of detectable levels of serum prostate specific antigen after radical prostatectomy. J. Urol. 1994 152 : 1821 5.
82. Zincke H, Oesterling JE, Blute ML et al. Long-term (15 years) results after radical prostatectomy for clinically localized (stage T2c or lower) prostate cancer. J. Urol. 1994 152 : 1850 7.
83. Han M, Partin AW, Pound CR et al. Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy. The 15-year Johns Hopkins experience. Urol. Clin. North Am. 2001 28 : 555 65.
84. Hull GW, Rabbani F, Abbas F et al. Cancer control with radical prostatectomy alone in 1,000 consecutive patients. J. Urol. 2002 167 : 528 34.
85. Lau WK, Bergstralh EJ, Blute ML et al. Radical prostatectomy for pathological Gleason 8 or greater prostate cancer: influence of concomitant pathological variables. J. Urol. 2002 167 : 117 22.
86. van den Ouden D, Hop WC, Schroder FH. Progression in and survival of patients with locally advanced prostate cancer (T3) treated with radical prostatectomy as monotherapy. J. Urol. 1998 160 : 1392 7.
87. Alibhai SM, Naglie G, Nam R et al. Do older men benefit from curative therapy of localized prostate cancer? J. Clin. Oncol. 2003 21 : 3318 27.
88. Coen JJ, Zietman AL, Shipley WU. Prostatectomy or watchful waiting in prostate cancer. N. Engl. J. Med. 2003 348 : 170 1 author reply 170 1.
89. Grimm MO, Kamphausen S, Hugenschmidt H et al. Clinical outcome of patients with lymph node positive prostate cancer after radical prostatectomy versus androgen deprivation. Eur. Urol. 2002 41 : 628 34.
90. Lu-Yao GL, McLerran D, Wasson J et al. An assessment of radical prostatectomy. Time trends, geographic variation, and outcomes. The Prostate Patient Outcomes Research Team. JAMA 1993 269 : 2633 6.
91. Eastham JA, Kattan MW, Riedel E et al. Variations among individual surgeons in the rate of positive surgical margins in radical prostatectomy specimens. J. Urol. 2003 170 : 2292 5.
92. Van Poppel H, Collette L, Kirkali Z et al. EORTC GU Group. Quality control of radical prostatectomy: a feasibility study. Eur. J. Cancer 2001 37 : 884 9.
93. Soloway MS, Pareek K, Sharifi R et al. Neoadjuvant androgen ablation before radical prostatectomy in cT2bNxMo prostate cancer: 5-year results. J. Urol. 2002 167 : 112 16.
94. Aus G, Abrahamsson PA, Ahlgren G et al. Three-month neoadjuvant hormonal therapy before radical prostatectomy: a 7-year follow-up of a randomized controlled trial. BJU Int. 2002 90 : 561 6.
95. Klotz LH, Goldenberg SL, Jewett MA et al. Long-term followup of a randomized trial of 0 versus 3 months of neoadjuvant androgen ablation before radical prostatectomy. J. Urol. 2003 170 : 791 4.
96. Salomon L, Anastasiadis AG, Levrel O et al. Location of positive surgical margins after retropubic, perineal, and laparoscopic radical prostatectomy for organ-confined prostate cancer. Urology 2003 61 : 386 90.
97. Artibani W, Grosso G, Novara G et al. Is laparoscopic radical prostatectomy better than traditional retropubic radical prostatectomy? An analysis of peri-operative morbidity in two contemporary series in Italy. Eur. Urol. 2003 44 : 401 6.
98. Lance RS, Freidrichs PA, Kane C et al. A comparison of radical retropubic with perineal prostatectomy for localized prostate cancer within the Uniformed Services Urology Research Group. BJU Int. 2001 87 : 61 5.
99. Lodding P, Bergdahl C, Nyberg M et al. Inguinal hernia after radical retropubic prostatectomy for prostate cancer: a study of incidence and risk factors in comparison to no operation and lymphadenectomy. J. Urol. 2001 166 : 964 7.
100. Lu-Yao GL, Albertsen P, Warren J et al. Effect of age and surgical approach on complications and short-term mortality after radical prostatectomy - a population-based study. Urology 1999 54 : 301 7.
101. Bishoff JT, Motley G, Optenberg SA et al. Incidence of fecal and urinary incontinence following radical perineal and retropubic prostatectomy in a national population. J. Urol. 1998 160 : 454 8.
102. Abbou CC, Salomon L, Hoznek A et al. Laparoscopic radical prostatectomy: preliminary results. Urology 2000 55 : 630 4.
103. Guillonneau B, el-Fettouh H, Baumert H et al. Laparoscopic radical prostatectomy: oncological evaluation after 1,000 cases a Montsouris Institute. J. Urol. 2003 169 : 1261 6.
104. Rassweiler J, Sentker L, Seemann O et al. Laparoscopic radical prostatectomy with the Heilbronn technique: an analysis of the first 180 cases. J. Urol. 2001 166 : 2101 8.
105. Arai Y, Egawa S, Terachi T et al. Morbidity of laparoscopic radical prostatectomy: summary of early multi-institutional experience in Japan. Int. J. Urol. 2003 10 : 430 4.
106. Marcovich R, Wojno KJ, Wei JT et al. Bladder neck-sparing modification of radical prostatectomy adversely affects surgical margins in pathologic T3a prostate cancer. Urology 2000 55 : 904 8.
107. Stanford JL, Feng Z, Hamilton AS et al. Urinary and sexual function after radical prostatectomy for clinically localized prostate cancer: the Prostate Cancer Outcomes Study. JAMA 2000 283 : 354 60.
108. Sokoloff MH, Brendler CB. Indications and contraindications for nerve-sparing radical prostatectomy. Urol. Clin. North Am. 2001 28 : 535 43.
109. Robinson JW, Moritz S, Fung T. Meta-analysis of rates of erectile function after treatment of localized prostate carcinoma. Int. J. Radiat. Oncol. Biol. Phys. 2002 54 : 1063 8.
110. Clark T, Parekh DJ, Cookson MS et al. Randomized prospective evaluation of extended versus limited lymph node dissection in patients with clinically localized prostate cancer. J. Urol. 2003 169 : 145 7.
111. Heidenreich A, Varga Z, Von Knobloch R. Extended pelvic lymphadenectomy in patients undergoing radical prostatectomy: high incidence of lymph node metastasis. J. Urol. 2002 167 : 1681 6.
112. Freedland SJ, Sutter ME, Dorey F et al. Defining the ideal cutpoint for determining PSA recurrence after radical prostatectomy. Prostate-specific antigen. Urology 2003 61 : 365 9.
113. Leibman BD, Dillioglugil O, Wheeler TM et al. Distant metastasis after radical prostatectomy in patients without an elevated serum prostate specific antigen level. Cancer 1995 76 : 2530 4.
114. Lattouf JB, Saad F. Digital rectal exam following prostatectomy: is it still necessary with the use of PSA? Eur. Urol. 2003 43 : 333 6.
115. Niwakawa M, Tobisu K, Fujimoto H et al. Medically and economically appropriate follow-up schedule for prostate cancer patients after radical prostatectomy. Int. J. Urol. 2002 9 : 134 40.
116. Messing EM, Manola J, Sarosdy M et al. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N. Engl. J. Med. 1999 341 : 1781 8.
117. Pisansky TM, Kozelsky TF, Myers RP et al. Radiotherapy for isolated serum prostate specific antigen elevation after prostatectomy for prostate cancer. J. Urol. 2000 163 : 845 50.
118. Duchesne GM, Dowling C, Frydenberg M et al. Outcome, morbidity, and prognostic factors in post-prostatectomy radiotherapy: an Australian multicenter study. Urology 2003 61 : 179 83.
119. Song DY, Thompson TL, Ramakrishnan V et al. Salvage radiotherapy for rising or persistent PSA after radical prostatectomy. Urology 2002 60 : 281 7.
120. Macdonald OK, Schild SE, Vora SA et al. Radiotherapy for men with isolated increase in serum prostate specific antigen after radical prostatectomy. J. Urol. 2003 170 : 1833 7.
121. Katz MS, Zelefsky MJ, Venkatraman ES et al. Predictors of biochemical outcome with salvage conformal radiotherapy after radical prostatectomy for prostate cancer. J. Clin. Oncol. 2003 21 : 483 9.
122. Catton C, Gospodarowicz M, Warde P et al. Adjuvant and salvage radiation therapy after radical prostatectomy for adenocarcinoma of the prostate. Radiother. Oncol. 2001 59 : 51 60.
123. Schild SE. Radiation therapy (RT) after prostatectomy: the case for salvage therapy as opposed to adjuvant therapy. Int. J. Cancer 2001 96 : 94 8.
124. Zietman AL, Chung CS, Coen JJ et al. 10-year outcome for men with localized prostate cancer treated with external radiation therapy: results of a cohort study. J. Urol. 2004 171 : 210 14.
125. Pilepich MV, Krall JM, John MJ et al. Hormonal cytoreduction in locally advanced carcinoma of the prostate treated with definitive radiotherapy: preliminary results of RTOG 83-07. Int. J. Radiat. Oncol. Biol. Phys. 1989 16 : 813 77.
126. Pilepich MV, Caplan R, Byhardt RW et al. Phase trial of androgen suppression using goserelin in unfavorable prognosis carcinoma of the prostate treated with definitive radiotherapy: report of RTOG 85-31. J. Clin. Oncol. 1997 15 : 1013 121.
127. Pilepich MV, Winter K, Lawton CA et al. Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma-long term results of phase RTOG study 85-31. Int. J. Radiat. Oncol. Biol. Phys. 2005 61 : 1285 190.
128. Lawton CA, Winter K, Murray K et al. Updated results of the phase RTOG trial 85-31 evaluating the potential benefit of androgen suppression following standard radiation therapy for unfavorable prognosis carcinoma of the prostate. Int. J. Radial Oncol. Biol. Phys. 2001 49 : 937 146.
129. Bolla M, Gonzalez D, Warde P et al. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N. Engl. J. Med. 1997 337 : 295 300.
130. Bolla M, Collette L, Blank L et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study). Lancet 2002 360 : 103 6.
131. Pilepich MV, Krall JM, Al-Sarraf M et al. Androgen deprivation with radiation therapy compared with radiation therapy alone for locally advanced prostatic carcinoma: a randomized comparative trial of the Radiation Therapy Oncology Group. Urology 1995 45 : 616 23.
132. Pilepich MV, Winter K, John MJ et al. Phase radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate. Int. J. Radiat. Oncol. Biol. Phys. 2001 50 : 1243 52.
133. Hanks GE, Pajak TF, Porter A et al. Phase trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: the Radiation Therapy Oncology Group Protocol 92-02. J. Clin. Oncol. 2003 21 : 3972 28.
134. Roach M 3rd, DeSilvio M, Lawton C et al. Phase trial comparing whole-pelvic versus prostate-only radiotherapy and neoadjuvant versus adjuvant combined androgen suppression: Radiation Therapy Oncology Group 9413. J. Clin. Oncol. 2003 21 : 1904 11.
135. D'Amico AV, Manola J, Loffredo M et al. 6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial. JAMA 2004 292 : 821 7.
136. D'Amico A, Whittington R, Malkowicz S et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998 280 : 969 74.
137. Roach M, Lu J, Pilepich MV et al. Four prognostic groups predict long-term survival from prostate cancer following radiotherapy alone on radiation therapy oncology group clinical trials. Int. J. Radiat. Oncol. Biol. Phys. 2000 47 : 609 15.
138. Kattan M, Zelefsky M, Kupelian P et al. Pretreatment nomogram for predicting the outcome of three-dimensional conformal radiotherapy in prostate cancer. J. Clin. Oncol. 2000 18 : 3352 9.
139. Pollack A, Zagars GK, Starkschall G et al. Prostate cancer radiation dose-response: results of the M.D. Anderson Phase randomized trial. Int. J. Radiat. Oncol. Biol. Phys. 2002 53 : 1097 105.
140. Deger S, Boehmer D, Turk I et al. High dose rate brachytherapy of localized prostate cancer. Eur. Urol. 2002 41 : 420 6.
141. Wallner K, Merrick G, True L et al. 125I versus 103Pd for low-risk prostate cancer: preliminary PSA outcome from a prospective randomized multicenter trial. Int. J. Radiat. Oncol. Biol. Phys. 2003 57 : 1297 303.
142. American Society for Therapeutic Radiology and Oncology Consensus Panel Consensus statement. Guidelines for PSA following radiation therapy. American Society for Therapeutic Radiology and Oncology Consensus Panel. Int. J. Radiat. Oncol. Biol. Phys. 1997 37 : 1035 341.
143. Vicini FA, Kestin LL, Martinez AA. The importance of adequate follow-up in defining treatment success after external beam irradiation for prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 1999 45 : 553 61.
144. Taylor JM, Griffith KA, Sandler HM. Definitions of biochemical failure in prostate cancer following radiation therapy. Int. J. Radiat. Oncol. Biol. Phys. 2001 50 : 1212 19.
145. Pollack A, Zagars GK, Antolak JA et al. Prostate biopsy status and PSA nadir level as early surrogates for treatment failure: analysis of a prostate cancer randomized radiation dose escalation trial. Int. J. Radiat. Oncol. Biol. Phys. 2002 54 : 677 85.
146. Tsushima T, Nasu Y, Saika T et al. Optimal starting time for flutamide to prevent disease flare in prostate cancer patients treated with a gonadotropin-releasing hormone agonist. Urol. Int. 2001 66 : 135 9.
147. Boccardo F, Rubagotti A, Battaglia M et al. Evaluation of tamoxifen and anastrozole in the prevention of gynecomastia and breast pain induced by bicalutamide monotherapy of prostate cancer. J. Clin. Oncol. 2005 23 : 808 015.
148. Wirth M, Tyrrell C, Wallace M, et al. Bicalutamide (Casodex) 150 mg as immediate therapy in patients with localized or locally advanced prostate cancer significantly reduces the risk of disease progression. Urology 2001 58 : 146 4151.
149. See W, Iversen P, Wirth M, McLeod D, Garside L, Morris T. Immediate treatment with bicalutamide 150 mg as adjuvant therapy significantly reduces the risk of PSA progression in early prostate cancer. Eur. Urol. 2003 44 : 512 7 discussion 517 18.
150. Iversen P, Johansson JE, Lodding P, et al. Scandinavian Prostatic Cancer Group. Bicalutamide (150 mg) versus placebo as immediate therapy alone or as adjuvant to therapy with curative intent for early nonmetastatic prostate cancer: 5.3 year median followup from the Scandinavian Prostate Cancer Group Study Number 6. J. Urol. 2004 172 : 1871 86.
151. Medical Research Council Prostate Cancer Working Party Investigators Group. Immediate versus deferred treatment for advanced prostate cancer: initial results of the Medical Research Council Trial. Br. J. Urol. 1997 79 : 235 3246.
152. Labrie F, Dupont A, Belanger A, et al. Combination therapy with flutamide and castration (LHRH agonist or orchiectomy) in advanced prostate cancer: a marked improvement in response and survival. J. Steroid Biochem. 1985 23 : 833 3841.
153. Prostate Cancer Trialists 'Collaborative Group. Maximum androgen blockade in advanced prostate cancer: an overview of 22 randomised trials with 3283 deaths in 5710 patients. Lancet 1995 346 : 265 6269.
154. Prostate Cancer Trialists 'Collaborative Group. Maximal androgen blockade in advanced prostate cancer: an overview of the randomised trials. Lancet 2000 355 : 1491 41498.
155. Eisenberger MA, Blumenstein BA, Crawford ED, et al. Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. N. Engl. J. Med. 1998 339 : 1036 42.
156. Schmitt B, Wilt TJ, Schellhammer PF, et al. Combined androgen blockade with nonsteroidal antiandrogens for advanced prostate cancer: a systematic review. Urology 2001 57 : 727 2732.
157. Samson DJ, Seidenfeld J, Schmitt B, et al. Systematic review and meta-analysis of monotherapy compared with combined androgen blockade for patients with advanced prostate carcinoma. Cancer 2002 95 : 361 6376.
158. Klotz L. Combined androgen blockade in prostate cancer: meta-analyses and associated issues. BJU Int. 2001 87 : 806 013.
159. Tannock IF, de Wit R, Berry WR et al. 327 Investigators. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N. Engl. J. Med. 2004 351 : 1502 12.
160. Petrylak DP, Tangen CM, Hussain MH et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N. Engl. J. Med. 2004 351 : 1513 20.
161. Holmberg L, Bill-Axelson A, Helgesen F et al. A randomized trial comparing radical prostatectomy with watchful waiting in early prostate cancer. N. Engl. J. Med. 2002 347 : 781 9.
162. Bill-Axelson A, Holmberg L, Ruutu M et al. Radical prostatectomy versus watchful waiting in early prostate cancer. N. Engl. J. Med. 2005 352 : 1977 84.
163. Chodak GW, Thisted RA, Gerber GS et al. Results of conservative management of clinically localized prostate cancer. N. Engl. J. Med. 1994 330 : 242 8.
164. Carter CA, Donahue T, Sun L et al. Temporarily deferred therapy (watchful waiting) for men younger than 70 years and with low-risk localized prostate cancer in the prostate-specific antigen era. J. Clin. Oncol. 2003 21 : 4001 8.
165. Choo R, Klotz L, Danjoux C et al. Feasibility study: watchful waiting for localized low to intermediate grade prostate carcinoma with selective delayed intervention based on prostate specific antigen, histological and/or clinical progression. J. Urol. 2002 167 : 1664 9.
166. Cooperberg MR, Broering JM, Litwin MS et al. The contemporary management of prostate cancer in the United States: lessons from the cancer of the prostate strategic urologic research endeavor (CapSURE, a national disease registry. J. Urol. 2004 171 : 1393 401.
167. Bacon CG, Giovannucci E, Testa M et al. The impact of cancer treatment on quality of life outcomes for patients with localized prostate cancer. J. Urol. 2001 166 : 1804 10.
168. George N. Therapeutic dilemmas in prostate cancer: justification for watchful waiting. Eur Urol. 1998 34 (Suppl 3 33 6.
169. Kakehi Y. Watchful waiting as a treatment option for localized prostate cancer in the PSA era. Jpn. J. Clin. Oncol. 2003 33 : 1 5.
170. Smith JA Jr, Soloway MS, Young MJ. Complications of advanced prostate cancer. Urology 1999 54 (6A Suppl 8 14.
171. Scher HI, Chung LW. Bone metastases: improving the therapeutic index. Semin. Oncol. 1994 21 : 630 356.
172. Japanese Society for Palliative Medicine, creation Committee of the clinical guideline for pain control in cancer patient. Evidence-Based Guideline for Pain Control in Cancer Patient. Shinko Trading Co., LTD., Tokyo, 2000.
173. Arcangeli G, Giovinazzo G, Saracino B et al. Radiation therapy in the management of symptomatic bone metastases: the effect of total dose and histology on pain relief and response duration. Int. J. Radiat. Oncol. Biol. Phys. 1998 42 : 1119 26.
174. Bolger JJ, Dearnaley DP, Kirk D et al. Strontium-89 (Metastron) versus external beam radiotherapy in patients with painful bone metastases secondary to prostatic cancer: preliminary report of a multicenter trial. UK Metastron Investigators Group. Semin. Oncol. 1993 20 (3 Suppl 2 32 23.
175. Quilty PM, Kirk D, Bolger JJ et al. A comparison of the palliative effects of strontium-89 and external beam radiotherapy in metastatic prostate cancer. Radiother. Oncol. 1994 31 : 33 40.
176. Saad F, Gleason DM, Murray R et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J. Natl. Cancer Inst. 2002 94 : 1458 68.
177. Ross JR, Saunders Y, Edmonds PM et al. Systematic review of role of bisphosphonates on skeletal morbidity in metastatic cancer. BMJ 2003 327 (7413 469.
178. Sorensen S, Helweg-Larsen S, Mouridsen H et al. Effect of high-dose dexamethasone in carcinomatous metastatic spinal cord compression treated with radiotherapy: a randomised trial. Eur. J. Cancer 1994 30A : 22 7.
179. Young RF, Post EM, King GA. Treatment of spinal epidural metastases. Randomized prospective comparison of laminectomy and radiotherapy. J. Neurosurg. 1980 53 : 741 8.
180. Crain DS, Amling CL, Kane CJ. Palliative transurethral prostate resection for bladder outlet obstruction in patients with locally advanced prostate cancer. J. Urol. 2004 171 : 668 71.
181. Kraus PA, Lytton B, Weiss RM, Prosnitz LR. Radiation therapy for local palliative treatment of prostatic cancer. J. Urol. 1972 108 : 612 14.
182. Oefelein MG. Prognostic significance of obstructive uropathy in advanced prostate cancer. Urology 2004 63 : 1117 21.
183. Watkinson AF, A'Hern RP, Jones A et al. The role of percutaneous nephrostomy in malignant urinary tract obstruction. Clin. Radiol. 1993 47 : 32 25.
184. Docimo SG, Dewolf WC. High failure rate of indwelling ureteral stents in patients with extrinsic obstruction: experience at 2 institutions. J. Urol. 1989 142 : 277 9.
185. Hasegawa T. Appraisal of Guidelines for Research and Evaluation Agree Instrument. [Cited 15 October 2004.] Available from URL: http://www.mnc.toho-u. ac.jp/mmc/guideline/AGREE-final.pdf